27 Results for "

p-SCN-Bn-DOTA

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "p-SCN-Bn-DOTA" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-114377
CAS No.: 127985-74-4
Purity:  99.78%
Research Areas:  

Cancer

p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P2336A
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
loading...
    loading...
Cat. No.: HY-156038
CAS No.: 1020407-41-3
Purity:  99.75%
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
loading...
    loading...
Cat. No.: HY-P11287A
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
Cat. No.: HY-P10131
CAS No.: 2803421-14-7
Research Areas:  

Cancer

3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .
loading...
    loading...
Cat. No.: HY-P2112
CAS No.: 619300-53-7
Synonyms: DOTA-Nal3-octreotide
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-114377R
CAS No.: 127985-74-4
Target:  

Others

Research Areas:  

Cancer

p-SCN-Bn-DOTA (Standard) is the analytical standard of p-SCN-Bn-DOTA. This product is intended for research and analytical applications. p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .
loading...
    loading...
Cat. No.: HY-P10273A
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P11287
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ 225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .
loading...
    loading...
Cat. No.: HY-164981
CAS No.: 1703752-99-1
Target:  

Drug Intermediate

Research Areas:  

Cancer

p-SCN-Bn-DOTA(tBu)4 is the derivative of DOTA (HY-W053583). p-SCN-Bn-DOTA(tBu)4 is the component of the Gd(III)-DOTA-IAC, which is a targeted magnetic resonance imaging (MRI) contrast agent for αvβ3 integrin receptor .
loading...
    loading...
Cat. No.: HY-P11026
Synonyms: DOTA-PEG4-TMVP1446
Target:  

VEGFR

Research Areas:  

Cancer

DOTA-TMVP1446 is a VEGFR-3 targeting peptide. DOTA-TMVP1446 labeled with 68Ga accurately detectes the status of lymph node metastasis, even in micrometastatic tumors, in the B16-F10 tumor mice model. DOTA-TMVP1446 can be used as a radiotracer for cancer-metastatic sentinel lymph nodes (m-SLN) imaging .
loading...
    loading...
Cat. No.: HY-P11253
Target:  

VISTA

Research Areas:  

Inflammation/Immunology

DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ 68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .
loading...
    loading...
Cat. No.: HY-P10444
CAS No.: 3033865-40-3
Research Areas:  

Cancer

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P5297
Research Areas:  

Cancer

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-156038B
Target:  

Drug Derivative

Research Areas:  

Cancer

(S)-p-SCN-Bn-DOTA TFA is a bifunctional chelator (BFC), a macrocyclic DOTA (HY-W053583) derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA TFA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
loading...
    loading...
Cat. No.: HY-P10307
Research Areas:  

Infection

DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P10951
CAS No.: 2647371-60-4
Synonyms: (R)-PSMA I&T; (R)-PNT-2002
Target:  

PSMA

Research Areas:  

Cancer

Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
loading...
    loading...
Cat. No.: HY-P10273
CAS No.: 209277-09-8
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-P11613
Target:  

EGFR

Research Areas:  

Cancer

DOTA-WC8 is a HER2-targeting peptide probe with a KD of 61.20 nM. 68Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .
loading...
    loading...
Cat. No.: HY-P11553B
CAS No.: 2850189-48-7
DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .
loading...
    loading...